CLN1 gene therapy - Amicus Therapeutics
Alternative Names: CLN1 Batten Disease - Amicus TherapeuticsLatest Information Update: 28 Feb 2025
At a glance
- Originator Nationwide Children's Hospital; Ohio State University
- Developer Amicus Therapeutics; Nationwide Children's Hospital
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuronal ceroid lipofuscinosis
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Neuronal ceroid lipofuscinosis in USA (Intrathecal)
- 13 Jan 2021 Preclinical trials in Neuronal ceroid lipofuscinosis in USA (Intrathecal)
- 08 Feb 2019 Early research in Neuronal ceroid lipofuscinosis in USA (Parenteral) before February 2019 (Amicus Therapeutics Pipeline)